8-K filing — ACCENDRA HEALTH INC/VA/ (ACH)
Filed: 2026-08-17 AccNo: 0001104659-26-097517 Size: 203 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Accendra Health Lowers FY2026 Sales Guidance from $2.550B-$2.650B to $2.450B-$2.550B vs $2.574B Est
Accendra Health (NYSE:ACH) lowers FY2026 sales outlook from $2.550 billion-$2.650 billion to $2.450 billion-$2.550 billion vs $2.574 billion estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Accendra Health Updates Capital Plans; Nets $45M From Non-Core Asset Sales And Sets CEO Succession Timeline For September
Accendra Health (the "Company") is providing an update on its capital allocation plans and the timeline for the replacement of its chief executive officer.Given recent market conditions, the Company has
UBS Maintains Neutral on Accendra Health, Lowers Price Target to $1.5
UBS analyst Kevin Caliendo maintains Accendra Health (NYSE:ACH) with a Neutral and lowers the price target from $4.5 to $1.5.
Accendra Health shares are trading lower after Citigroup downgraded the stock from Buy to Neutral rating and lowered the price target from $4.5 to $1.5.